CaRi-heart technology
Revolutionary new technology to assess the risk of a serious heart condition or heart attack – many years before anything happens.
These are the details of all previous panels, including panel revisions and updates, that we have previously used. For details of our current NGS panels see this page.
This information is thus provided for legacy support purposes only.
Please note: For all of the assays detailed below, sequence data (from the specified regions) will only be assessed for the presence of unique coding variants contained within version 79 of the COSMIC database. Any variants outside of this designation are not routinely assessed or reported.
The first version of our in-house developed NGS panel.
The second version of our in-house developed NGS panel.
The third version of our in-house developed NGS panel.
Unfortunately, as of 14/01/2026, Sarah Cannon Molecular Diagnostics is now closed to all external business. Our contact details remain live should you need contact us for any information or support relating to previous cases.